Literature DB >> 12493149

Toxicity of treatment for neoplastic meningitis.

Tali Siegal1.   

Abstract

Neoplastic seeding of the leptomeninges often signifies limited life expectancy. Still, patients are frequently offered aggressive multimodality therapies to palliate symptoms, and, one hopes, to prolong survival. Treatment modalities directed at the central nervous system (CNS) include radiotherapy, intra-cerebrospinal fluid (CSF) chemotherapy, standard systemic chemotherapy, and systemic high-dose chemotherapy. Because many of these modalities are used in combination, it is often difficult to discern which mode is the predominant cause of either acute or delayed complications. This review summarizes the incidence, clinical manifestations, laboratory findings, and pathology related to acute and delayed toxicity of treatment. It describes complications associated with radiotherapy, the use of an intraventricular implanted device (ie, Ommaya device), adverse effects of intra-CSF chemotherapy, and neurotoxicity, either associated with high-dose chemotherapy or manifested as delayed and chronic complications of combined therapies. All CNS-directed therapies are associated with a high rate of complications. The adverse effects of therapy profoundly affect the patient's quality of life, both at the acute phase of treatment and in late and chronic complications after therapy is completed. Intra-CSF chemotherapy is associated with a high rate of acute, reversible adverse effects that sometimes evolve into life-threatening medical conditions. Devastating delayed complications, mainly described as leukoencephalopathy, develop in more than 50% of patients who survive for extended periods and often lead to progressive loss of cognitive capacities. Careful assessment of the benefits and potential adverse reactions to a particular therapy regimen is mandated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12493149     DOI: 10.1007/s11912-003-0085-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  60 in total

1.  Evidence for cerebellar-frontal subsystem changes in children treated with intrathecal chemotherapy for leukemia: enhanced data analysis using an effect size model.

Authors:  P G Lesnik; K T Ciesielski; B L Hart; E C Benzel; J A Sanders
Journal:  Arch Neurol       Date:  1998-12

2.  Central nervous system toxicity of high-dose cytosine arabinoside.

Authors:  M J Barnett; M A Richards; T S Ganesan; J H Waxman; B F Smith; M G Butler; A Z Rohatiner; M L Slevin; T A Lister
Journal:  Semin Oncol       Date:  1985-06       Impact factor: 4.929

3.  Methotrexate induced brain necrosis and severe leukoencephalopathy due to disconnection of an Ommaya device.

Authors:  R de Waal; P R Algra; J J Heimans; J G Wolbers; P Scheltens
Journal:  J Neurooncol       Date:  1993-03       Impact factor: 4.130

4.  A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis.

Authors:  R N Hitchins; D R Bell; R L Woods; J A Levi
Journal:  J Clin Oncol       Date:  1987-10       Impact factor: 44.544

5.  Computerized tomography scan findings in children with acute lymphocytic leukemia treated with three different methods of central nervous system prophylaxis.

Authors:  M L Brecher; P Berger; A I Freeman; J Krischer; J Boyett; A S Glicksman; E Foreman; M Harris; B Jones; M E Cohen
Journal:  Cancer       Date:  1985-11-15       Impact factor: 6.860

Review 6.  Filamentous degeneration of neurons. A possible feature of cytosine arabinoside neurotoxicity.

Authors:  H Vogel; D S Horoupian
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

7.  Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group.

Authors:  S A Grossman; D M Finkelstein; J C Ruckdeschel; D L Trump; T Moynihan; D S Ettinger
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

8.  Management of infectious complications of intraventricular reservoirs in cancer patients: low incidence and successful treatment without reservoir removal.

Authors:  P A Dinndorf; W A Bleyer
Journal:  Cancer Drug Deliv       Date:  1987

9.  Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.

Authors:  K Fizazi; B Asselain; A Vincent-Salomon; M Jouve; V Dieras; T Palangie; P Beuzeboc; T Dorval; P Pouillart
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

10.  Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside. A Pediatric Oncology Group study.

Authors:  S F Dunton; R Nitschke; W E Spruce; J Bodensteiner; H F Krous
Journal:  Cancer       Date:  1986-03-15       Impact factor: 6.860

View more
  5 in total

1.  Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series.

Authors:  Marc C Chamberlain
Journal:  J Neurooncol       Date:  2012-04-27       Impact factor: 4.130

Review 2.  Leptomeningeal metastases from solid malignancy: a review.

Authors:  Sophie Taillibert; Florence Laigle-Donadey; Catherine Chodkiewicz; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

3.  Contrast-Enhancing Meningeal Lesions Are Associated with Longer Survival in Breast Cancer-Related Leptomeningeal Metastasis.

Authors:  Anne Constanze Regierer; Andrea Stroux; Dagmar Kühnhardt; Annette Dieing; Silvia Lehenbauer-Dehm; Bernd Flath; Kurt Possinger; Jan Eucker
Journal:  Breast Care (Basel)       Date:  2008-04-15       Impact factor: 2.860

Review 4.  Central nervous system toxicity from cancer treatment.

Authors:  Terri Armstrong; Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

5.  Carcinomatous meningitis: Leptomeningeal metastases in solid tumors.

Authors:  Emilie Le Rhun; Sophie Taillibert; Marc C Chamberlain
Journal:  Surg Neurol Int       Date:  2013-05-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.